Advanced Therapeutics for Rheumatoid Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that participants must have failed treatments with methotrexate, hydroxychloroquine, sulfasalazine, and Leflunomide, which suggests that you may need to have tried these medications before joining the trial.
What safety data is available for Etanercept in treating rheumatoid arthritis?
Etanercept, also known as Enbrel, has been shown to be safe in treating rheumatoid arthritis, with rapid, dose-dependent improvements observed over 3 months in a phase II study. Common minor side effects include injection site reactions and upper respiratory tract infections, which typically do not require discontinuation of the medication. Some patients have reported an urticaria-like rash. Overall, Etanercept has demonstrated significant improvements in rheumatoid arthritis symptoms in placebo-controlled trials.12345
Is the drug Etanercept, Tofacitinib a promising treatment for rheumatoid arthritis?
What data supports the idea that Advanced Therapeutics for Rheumatoid Arthritis is an effective treatment?
The available research shows that Advanced Therapeutics for Rheumatoid Arthritis, specifically etanercept, is effective in treating the condition. One study found that etanercept led to rapid improvement in symptoms over three months. Another study showed that adding etanercept to methotrexate, a common treatment, provided additional benefits for patients who still had active disease. Additionally, research on children with juvenile rheumatoid arthritis indicated that etanercept was effective for those who did not respond well to methotrexate. These studies suggest that etanercept can be a beneficial option for managing rheumatoid arthritis.13679
Who Is on the Research Team?
Janet E Pope, MD MPH
Principal Investigator
Western University, Canada
Are You a Good Fit for This Trial?
This trial is for adults with active Rheumatoid Arthritis who have at least 5 swollen joints, are seropositive, show joint erosion, and haven't responded to standard treatments like methotrexate. They must be able to consent and attend follow-up visits. It's not for those with serious infections, tuberculosis, multiple sclerosis, current or past cancer (including lymphoma), or previous advanced therapy use.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either etanercept or tofacitinib for the treatment of Rheumatoid Arthritis
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Etanercept
- Tofacitinib
Etanercept is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's
Lead Sponsor
London Health Sciences Centre OR Lawson Research Institute of St. Joseph's
Lead Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead Sponsor
Lawson Health Research Institute
Lead Sponsor
Academic Medical Organization of Southwestern Ontario
Collaborator